Catalyst Brief

← Calendar

Readoutin 104d

Novartis Pharmaceuticals — Ianalumab

Phase 3 primary completion: Phase 3 Study to Evaluate Two Regimens of Ianalumab on Top of Standard-of-care Therapy in Patients With Systemic Lupus Erythematosus (SIRIUS-SLE 1).

Date
Mar 2027
Type
Readout
Indication
Systemic Lupus Erythematosus

Source ↗Add to calendar

Get told when this date moves

The weekly brief is free. Pro adds reminders 7 days and 1 day before.

More from Novartis Pharmaceuticals

  1. May2027
  2. Apr2027